Disease response and patient-reported outcomes among initiators of ixekizumab

Abstract

Objectives

There is limited real-world evidence on using ixekizumab in psoriasis patients. Therefore, we characterized patients with psoriasis initiating ixekizumab and report 6-month changes in disease and patient-reported outcomes.

Methods

Adult patients with psoriasis who initiated ixekizumab and completed a 6-month follow-up visit were enrolled from the Corrona Psoriasis Registry. Disease characteristics and outcomes were assessed at ixekizumab initiation. Outcomes included the mean 6-month change in Psoriasis Area and Severity Index (PASI), body surface area (BSA), Investigator Global Assessment (IGA), and IGA*BSA.

Results

From baseline to follow-up in all patients (n = 136), means decreased for IGA*BSA (−45.5) and BSA (−12.4), and a higher % achieved an absolute PASI ≤ 5 (84.6%), BSA 0–3 (72.1%), and IGA 0/1 (50.7%). Within stratified groups, means decreased for PASI <12 for IGA*BSA (−21.1) and BSA (−6.3); PASI≥12 for IGA*BSA (−94.8) and BSA (−24.6); weight <100 kg for IGA*BSA (−45.1) and BSA (−12.4); weight ≥100 kg for IGA*BSA (−46.2) and BSA (−12.3); concomitant PsA for IGA*BSA (−56.0) and BSA (−15.3); and in no concomitant PsA for IGA*BSA (−36.9) and BSA (−10.0).

Conclusions

We provide real-world evidence on the benefits of ixekizumab for treating psoriasis, regardless of baseline disease severity, weight, or concomitant PsA.

Keywords:

• Biologics
• ixekizumab
• psoriasis
• treatment

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Acknowledgment

Medical writing services were provided by Michelle Karpman PhD, Corrona LLC.

Disclosure statement

Mona Shahriari, Central Connecticut Dermatology Research, Employee, Yale University, Employee, Speaker/Investigator for Eli Lily and Company; Ryan W Harrison, Corrona, LLC, Employee; Russel Burge, Eli Lilly and Company, Employee/Stock; Chen-Yen Lin, Eli Lilly and Company, Employee/Stock; William N Malatestinic, Eli Lilly and Company, Employee/Stock; Orin M Goldblum, Eli Lilly and Company, Employee/Stock; Robert R McLean, Corrona, LLC, Employee; Margaux Crabtree, Corrona, LLC, Employee; Elsie Grace, Eli Lilly and Company, Employee/Stock; Mwangi J Murage, Eli Lilly and Company, Employee/Stock.

Additional information

Funding

This study was funded by Eli Lilly and Company.